Region — International. Neutral scientific reference — not offered for sale here.

Set region

Explore Shop Tools Journal Trust

Explore  /  Tirzepatide

Research reference — not for sale

Tirzepatide

lead outcome

Type-2 diabetes glycemic control

grades vary by outcome ↓

Peptide

also called — tirzepatide · dual GIP/GLP-1 receptor agonist ("twincretin") · brands Mounjaro (T2D), Zepbound (obesity + OSA). Manufacturer: Eli Lilly. INCI: none · GLP-2-TZ · GLP-2 (T) · GLP2-TIRZ

metabolictype-2 diabetesobesity / weightobstructive sleep apnea (all approved)

Reference entry — NOT a sellable lane. Same status as semaglutide: an FDA-approved, patented blockbuster; compounded copies now largely prohibited. In the register for reference and completeness, not commerce. No dosing published here.

In brief

Tirzepatide is a dual GIP/GLP-1 agonist and, in the only head-to-head obesity trial (SURMOUNT-5), produced greater weight loss than semaglutide (−20.2% vs −13.7%). It is FDA-approved for type-2 diabetes (Mounjaro) and for obesity and obstructive sleep apnea (Zepbound), on a large Phase 3 base (grade A). Compounded copies are now largely prohibited following the December-2024 shortage resolution.

Legal standing, by region

European Union

Approved / prescription

approved as Mounjaro (and Zepbound in the US; brand naming varies by market).

United States

Approved / prescription

FDA-approved (Mounjaro / Zepbound; Eli Lilly only). Compounding: shortage declared resolved by the FDA (Declaratory Order, Dec 2024, all strengths); 503A enforcement discretion ended Feb 2025 → compounded tirzepatide now largely prohibited. Gray-market/counterfeit versions are unapproved and not FDA-reviewed.

Evidence, by outcome

How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade

Type-2 diabetes glycemic control

—

SURPASS Phase 3; FDA-approved · Robust HbA1c reduction (superior to semaglutide in SURPASS-2)

Chronic weight management (obesity)

Effect wanes if stopped; GI tolerability

SURMOUNT Phase 3 (~20–22%); SURMOUNT-5 head-to-head; FDA-approved · Substantial weight loss, greater than semaglutide

Obstructive sleep apnea (with obesity)

First drug approved for OSA

SURMOUNT-OSA; FDA-approved (2024) · Fewer breathing disruptions; ~½ no longer met OSA symptom threshold

Safety

GI effects (nausea/diarrhea/constipation/vomiting); labeled risks; clinical oversight

Large trials + post-marketing · Well-characterised

—

Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Tirzepatide changes - nothing else.

Identity

a single 39-amino-acid synthetic peptide (< 40 aa → peptide) that activates both the GIP and GLP-1 receptors (the two natural incretin hormones), with a C20 fatty-diacid for once-weekly dosing.

Mechanism (as proposed)

a dual agonist of the GIP and GLP-1 receptors — combining incretin pathways yields greater glycemic and weight effects than GLP-1 agonism alone (glucose-dependent insulin ↑, glucagon ↓, gastric emptying slowed, appetite ↓).

Related reading

See also (cosmetic): Skincare on GLP-1s — "Ozempic face". Rapid weight loss on this drug can drive visible facial changes (hollowing, laxity, lines); this is an appearance effect of fast weight loss, not a dosing or safety matter.

Sources — 1 cited

01SURPASS, SURMOUNT, SURMOUNT-OSA and SURMOUNT-5 (NEJM) Phase 3 programmes; FDA prescribing information (Mounjaro/Zepbound); FDA Declaratory Order resolving the tirzepatide shortage (Dec 2024).

Updated 2026-07-13

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds

Explore by goal

Metabolic →

Vallydia

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International

ExploreRegister The Register — full index Categories Trust & COA How we grade Open data Brands

ShopCosmetic peptides Journal Quizzes

TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.